alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
axdx_ex10133.htm

EXHIBIT 10.13.3 

 

 

AMENDMENT 

TO

12% PROMISSOPRY NOTE DUE 2016

 

OF

 

CO-DIAGNOSTICS, INC.

 

Original Principal Amount: $10,000

Original Issuance Date: February 22, 2016 

 

Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated February 22, 2016, as amended (the “Note”) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the “Company”) and Clavo Rico Incorporated, a Utah corporation (“Holder”);

 

Now therefore, the Note is hereby amended as follows:

 

The Maturity Date shall be September 30, 2017.

 

The Holder agrees that in the event the Company is able to file a Registration Statement for an Initial Public Offering on or before December 31, 2016, the Holder agrees to include the Note principal and accrued interest outstanding on the filing date with the Registration Statement and to convert all of the Note principal and accrued interest to Company common stock.  


The “Conversion Price” means shall be the same as the anticipated Bridge Financing to be provided by Alexander Capital, LP, as reflected in the Registration Statement.

 

All other terms and conditions of the Note, as amended, shall continue in full force and effect. 

 

IN WITNESS WHEREOF, the Parties have amended the Note effective as of September 14, 2016.

 

 


	
CO-DIAGNOSTICS, INC.
	
 
	
CLAVO RICO INCORPORATED

	
 
	
 
	
 

	
By: /s/ Dwight Egan
	
  
	
By: /s/ Reed Benson

	
Dwight H. Egan,
	
 
	
Reed L Benson, President

	
President & CEO
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1230 Calcium sulfate. ( a ) Calcium sulfate (CaSO4, CAS Reg. No. 7778-18-9 or CaSO4·2H2O, CAS Reg. No. 10101-41-4), also known as plaster of Paris, anhydrite, and gypsum, occurs naturally and exists as a fine, white to slightly yellow-white odorless powder. The anhydrous form is prepared by complete dehydration of gypsum, below 300 °C, in an electric oven.
( b ) The ingredient meets the specifications of the “Food Chemicals Codex,” 3d Ed. (1981), p. 66, which is incorporated by reference. Copies may be obtained from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) The ingredient is used as an anticaking agent as defined in § 170.3(o)(1) of this chapter, color and coloring adjunct as defined in § 170.3(o)(4) of this chapter, dough strengthener as defined in § 170.3(o)(6) of this chapter, drying agent as defined in § 170.3(o)(7) of this chapter, firming agent as defined in § 170.3(o)(10) of this chapter, flour treating agent as defined in § 170.3(o)(13) of this chapter, formulation aid as defined in § 170.3(o)(14) of this chapter, leavening agent as defined in § 170.3(o)(17) of this chapter, nutrient supplement as defined in § 170.3(o)(20) of this chapter, pH control agent as defined in § 170.3(o)(23) of this chapter, processing aid as defined in § 170.3(o)(24) of this chapter, stabilizer and thickener as defined in § 170.3(o)(28) of this chapter, synergist as defined in § 170.3(o)(31) of this chapter, and texturizer as defined in § 170.3(o)(32) of this chapter.
( d ) The ingredient is used in food at levels not to exceed good manufacturing practice in accordance with § 184.1(b)(1). Current good manufacturing practice results in a maximum level, as served, of 1.3 percent for baked goods as defined in § 170.3(n)(1) of this chapter, 3.0 percent for confections and frostings as defined in § 170.3(n)(9) of this chapter, 0.5 percent for frozen dairy desserts and mixes as defined in § 170.3(n)(20) of this chapter, 0.4 percent for gelatins and puddings as defined in § 170.3(n)(22) of this chapter, 0.5 percent for grain products and pastas as defined in § 170.3(n)(23) of this chapter, 0.35 percent for processed vegetables as defined in § 170.3(n)(36) of this chapter, and 0.07 percent or less for all other food categories.
( e ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[45 FR 6086, Jan. 25, 1980; 45 FR 26319, Apr. 18, 1980, as amended at 49 FR 5611, Feb. 14, 1984]
§ 212.60 What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products? ( a ) *Testing procedures.* Each laboratory used to conduct testing of components, in-process materials, and finished PET drug products must have and follow written procedures for the conduct of each test and for the documentation of the results.
( b ) *Specifications and standards.* Each laboratory must have sampling and testing procedures designed to ensure that components, in-process materials, and PET drug products conform to appropriate standards, including established standards of identity, strength, quality, and purity.
( c ) *Analytical methods.* Laboratory analytical methods must be suitable for their intended use and must be sufficiently sensitive, specific, accurate, and reproducible.
( d ) *Materials.* The identity, purity, and quality of reagents, solutions, and supplies used in testing procedures must be adequately controlled. All solutions that you prepare must be properly labeled to show their identity and expiration date.
( e ) *Equipment.* All equipment used to perform the testing must be suitable for its intended purposes and capable of producing valid results.
( f ) *Equipment maintenance.* Each laboratory must have and follow written procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained, and that these activities are documented.
( g ) *Test records.* Each laboratory performing tests related to the production of a PET drug must keep complete records of all tests performed to ensure compliance with established specifications and standards, including examinations and assays, as follows: ( 1 ) A suitable identification of the sample received for testing.
( 2 ) A description of each method used in the testing of the sample, a record of all calculations performed in connection with each test, and a statement of the weight or measurement of the sample used for each test.
( 3 ) A complete record of all data obtained in the course of each test, including the date and time the test was conducted, and all graphs, charts, and spectra from laboratory instrumentation, properly identified to show the specific component, in-process material, or drug product for each lot tested.
( 4 ) A statement of the results of tests and how the results compare with established acceptance criteria.
( 5 ) The initials or signature of the person performing the test and the date on which the test was performed.
###### Editorial Note on Part 172

#### Editorial Note:

Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 172.848 Lactylic esters of fatty acids.

Lactylic esters of fatty acids may be safely used in food in accordance with the following prescribed conditions:

(a) They are prepared from lactic acid and fatty acids meeting the requirements of § 172.860(b) and/or oleic acid derived from tall oil fatty acids meeting the requirements of § 172.862.

(b) They are used as emulsifiers, plasticizers, or surface-active agents in the following foods, when standards of identity do not preclude their use:

| Foods | Limitations |
| --- | --- |
| Bakery mixes | |
| Baked products | |
| Cake icings, fillings, and toppings | |
| Dehydrated fruits and vegetables | |
| Dehydrated fruit and vegetable juices | |
| Edible vegetable fat-water emulsions | As substitutes for milk or cream in beverage coffee. |
| Frozen desserts | |
| Liquid shortening | For household use. |
| Pancake mixes | |
| Precooked instant rice | |
| Pudding mixes | |

(c) They are used in an amount not greater than required to produce the intended physical or technical effect, and they may be used with shortening and edible fats and oils when such are required in the foods identified in paragraph (b) of this section.
<PAGE>   1

                                  EXHIBIT 23.1

CONSENT OF INDEPENDENT ACCOUNTANTS


As independent public accountants, we hereby consent to the incorporation of our
reports included in this Form 10-K, into the Company's previously filed
Registration Statement File No. 333-08717.

ARTHUR ANDERSEN LLP

Seattle, Washington
May 17, 1999
§ 11.10 Controls for closed systems. Persons who use closed systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records, and to ensure that the signer cannot readily repudiate the signed record as not genuine. Such procedures and controls shall include the following: ( a ) Validation of systems to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records.
( b ) The ability to generate accurate and complete copies of records in both human readable and electronic form suitable for inspection, review, and copying by the agency. Persons should contact the agency if there are any questions regarding the ability of the agency to perform such review and copying of the electronic records.
( c ) Protection of records to enable their accurate and ready retrieval throughout the records retention period.
( d ) Limiting system access to authorized individuals.
( e ) Use of secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. Record changes shall not obscure previously recorded information. Such audit trail documentation shall be retained for a period at least as long as that required for the subject electronic records and shall be available for agency review and copying.
( f ) Use of operational system checks to enforce permitted sequencing of steps and events, as appropriate.
( g ) Use of authority checks to ensure that only authorized individuals can use the system, electronically sign a record, access the operation or computer system input or output device, alter a record, or perform the operation at hand.
( h ) Use of device (e.g., terminal) checks to determine, as appropriate, the validity of the source of data input or operational instruction.
( i ) Determination that persons who develop, maintain, or use electronic record/electronic signature systems have the education, training, and experience to perform their assigned tasks.
( j ) The establishment of, and adherence to, written policies that hold individuals accountable and responsible for actions initiated under their electronic signatures, in order to deter record and signature falsification.
( k ) Use of appropriate controls over systems documentation including: ( 1 ) Adequate controls over the distribution of, access to, and use of documentation for system operation and maintenance.
( 2 ) Revision and change control procedures to maintain an audit trail that documents time-sequenced development and modification of systems documentation.
IIB 

118TH CONGRESS 

2D SESSION H. R. 7224 

IN THE SENATE OF THE UNITED STATES 

DECEMBER 17 (legislative day, DECEMBER 16), 2024 

Received; read twice and referred to the Committee on Health, Education, 

Labor, and Pensions 

AN ACT 

To amend the Public Health Service Act to reauthorize the 

Stop, Observe, Ask, and Respond to Health and Wellness 

Training Program. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

HR 7224 RFS

1 SECTION 1. REAUTHORIZATION OF THE SOAR TO HEALTH 

2 AND WELLNESS TRAINING PROGRAM. 

3 Section 1254(h) of the Public Health Service Act (42 

4 U.S.C. 300d–54(h)) is amended by striking ‘‘fiscal years 

5 2020 through 2024’’ and inserting ‘‘fiscal years 2025 

6 through 2029’’. 

Passed the House of Representatives December 16, 

2024. 

Attest: KEVIN F. MCCUMBER, 

Clerk. 


ssavage on LAPJG3WLY3PROD with BILLS
-       - Superintendent of Documents
      - 2023-09-02T15:47:56-0400
      - Government Publishing Office, Washington, DC 20401
      - Government Publishing Office
      - Government Publishing Office attests that this document has not been altered since it was disseminated by Government Publishing Office
#### SCOTT *v.*UNIVERSITY OF MICHIGAN ATHLETIC ASS’N.

Costs — Items Taxable — Stenosrapher’s Fees — Order of Court-—Necessity—Statute—Construction.

Under Act No. 183, Pub. Acts 1897 (sections 363-414, 1 Comp. Laws), which, expressly repeals and supersedes all special statutes heretofore in force in the several circuits, the expense of procuring a stenographer’s transcript of testimony to use in settling a bill of exceptions is taxable as costs, though no application was made to the circuit court for an order requiring the stenographer to furnish it free of cost.

Case by Frank W. Scott against the University of Michigan Athletic Association and others for personal injuries: On motion for retaxation of costs.

Submitted September 15, 1908.

(Calendar No. 22,452.)

Denied September 29, 1908.

*Arthur Brown*and *EIdson R.*Sunderland, for the motion.

*J. W, Bennett,*contra.

Per Curiam.

This is a motion to retax costs in this court. Appellant procured from the stenographer a copy of the testimony given at the trial for the purpose of settling a bill of exceptions, and the clerk has taxed the cost thereof over the objection made by appellees that, because no application was made to the circuit judge for an order requiring the stenographer to furnish a transcript free of cost, the expense of such transcript is not taxable as costs. See *Hayes*v. *Livingston,*35 Mich. 371; *Maynard*v. *Vinton,*59 Mich. 156; *Thurstin*v. *Luce,*61 Mich. 486; *City of Grand Rapids*v. *Coit,*151 Mich. 109. The question raised by this objection is the only one requiring discussion.

The case was tried in the Washtenaw circuit. The *329state of the law upon this subject prior to 1897 is shown in the note to Circuit Court Rule No. 47 (Stevens’ Ed.) Michigan Revised Rules of Practice. Act No. 183, Pub. Acts 1897 (1 Comp. Laws, §§ 363-414), entitled “An act to provide for the appointment and to fix the term of office, duties and compensation of circuit court stenographers in the State of Michigan,” contains an express provision for the taxation of such an item of expense as costs, and expressly repeals all acts and parts of acts contravening the provisions of that act. This statute supersedes the numerous special statutes theretofore in force, applies to all the circuits, and is authority for taxing the item objected to.

Motion to retax is denied, with costs.
EXHIBIT 32.1
 
 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 In connection with the Quarterly Report of Southwall Technologies Inc. (the "Company") on Form 10-Q for the quarter ended June 27, 2004 as filed with the Securities and Exchange Commission on the date hereof (the "Form 10-Q"), I, Thomas G. Hood, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
 2002, that:
 
 (1)
the Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  (2)
the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. 
 Date: August 11th, 2004/s/ Thomas G. HoodThomas G. HoodChief Executive Officer
 
 This Certification accompanies this Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent the Company specifically incorporates it by reference.
 
 A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnishes to the Securities and Exchange Commission or its staff upon request.
Page 1 of 3

Disposition Comments

Docket No: FAA-2015-2048 These comments are in

Directorate ID: 2015-CE-015-AD response to an SNPRM

Originating Office Tracking No.: 

Next Step: FRAN SNPRM

 No Comments/Only Supportive Comments Received – If this box is checked, no signatures are 

required.

No Has the referenced service information been revised since the NPRM was issued? If yes, 

list latest revision and attach a copy. Note that changes beyond the scope of the previously 

published NPRM will require a new notice. Contact the Directorate focal point for guidance.

Instructions: Summarize all comments by issue (not by commenter) and provide your recommended resolution of 

each issue. All comments relating to the same issue should be discussed together. Do not list all of the issues 

from one commenter together. If changes to the AD are required based on the comments received, explain why and 

describe in detail what change(s) you recommend. Reference FAA-IR-M-8040.1C Chapter 9.

ISSUE 1: Select one of the following: 

If other, explain: 

Commenter(s): 

What change to the AD action is requested? 

Why is the change requested or how is it justified? 

Do we agree? 

If YES, we agree because Make the following changes to the AD: 

If PARTIALLY AGREE, we agree with because We disagree with because 

Make the following changes to the AD: 

If NO, we don’t agree because 

ISSUE 2: Select one of the following: 

If other, explain: 

Commenter(s): 

What change to the AD action is requested? 

Why is the change requested or how is it justified? 

Do we agree? 

If YES, we agree because Make the following changes to the AD: 

If PARTIALLY AGREE, we agree with because We disagree with because 

Make the following changes to the AD:
Page 2 of 3

If NO, we don’t agree because 

For additional issues, double-click here
Page 3 of 3

Signature Section

Signature indicates concurrence with this action.

Originating Office Tracking No.: 

ASE Printed Name: Date

Branch Manager Date
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Balance
Sheet, Statement of Operations, Statements of Cash Flows and Notes thereto
incorporated in Part I, Item 1 of this Form 10-QSB and is qualified in its
entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1993
<PERIOD-END>                               JUN-30-1994
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        16,400
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                         0
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-BASIC>                                     0.00
<EPS-DILUTED>                                     0.00


</TABLE>
[No. 39316-2-I.

Division One.

December 1, 1997.]

#### The State of Washington, *Respondent,*v. G.C., *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 96-8-03252-4, Mary Wicks Brucker, J., entered September 4, 1996. *Reversed*by unpublished per curiam opinion.
#### § 207.55 What additional drug listing information may FDA require?

For a particular listed drug, upon our request, the registrant must briefly state the basis for its belief that the drug is not subject to section 505 or 512 of the Federal Food, Drug, and Cosmetic Act or section 351 of the Public Health Service Act.
§ 1114.29 FDA action on an application. After receipt of an application, FDA will: ( a ) Refuse to accept the application as described in § 1114.27(a);
( b ) Issue a letter administratively closing the application;
( c ) Issue a letter canceling the application if FDA finds that it mistakenly accepted the application or that the application was submitted in error;
( d ) Refuse to file the application as described in § 1114.27(b);
( e ) Issue a marketing granted order as described in § 1114.31; or
( f ) Issue a marketing denial order as described in § 1114.33.
<PAGE>   1

                                                                   EXHIBIT 23.3




June 9, 1998

To the Board of Directors of Forcenergy Inc:

We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (File No. 33-80919) of Forcenergy Inc of our reports
dated February 26, 1999, February 16, 1998 and February 7, 1997, and our
estimates of the net proved natural gas and oil reserves of Forcenergy, as of
January 1, 1999, 1998 and 1997, and to all references to our estimates of the
net proved natural gas and oil reserves of the Company as of those dates,
included in this Annual Report on form 10-K for the year ended December 31,
1998.

                                             COLLARINI ENGINEERING INC.



                                             /s/       CHERYL R. COLLARINI, P.E.
                                             ----------------------------------
                                             Cheryl R. Collarini, P.E.
                                             President